Skip to content

ANAVEX LIFE SCIENCES CORP.: 10-Q filed 2014-02-14

What ANAVEX LIFE SCIENCES CORP. reported in its quarterly report filed 2014-02-14 (fiscal Q1 2014): 21 published measures, 70 facts as tagged in accession 0001062993-14-000839.

This filing

Form
10-Q (quarterly report)
Filed
2014-02-14
Fiscal period
fiscal Q1 2014
Accession
0001062993-14-000839 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANAVEX LIFE SCIENCES CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-31150,887USD
At 2013-09-30393,449USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-311,821,141USD
At 2013-09-302,856,660USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-31-1,670,254USD
At 2013-09-30-2,463,211USD
At 2012-09-30-2,875,171USD
At 2011-09-30-1,142,404USD
At 2010-09-30-2,960,222USD
At 2009-09-30-3,857,823USD
At 2008-09-30-2,292,170USD
At 2007-09-30-462,504USD
At 2006-09-30-15,511USD
At 2005-09-30-26,020USD
At 2004-09-3025,605USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31358,637USD92
2004-01-23 to 2013-12-31-40,295,531USD3631
2012-10-01 to 2013-09-30-3,700,046USD365
2012-10-01 to 2012-12-31-453,517USD92
2011-10-01 to 2012-09-30-8,301,705USD366
2010-10-01 to 2011-09-30-7,307,147USD365
2009-10-01 to 2010-09-30-8,783,037USD365
2008-10-01 to 2009-09-30-5,499,419USD365
2007-10-01 to 2008-09-30-5,351,269USD366
2006-10-01 to 2007-09-30-1,579,993USD365
2005-10-01 to 2006-09-30-25,532USD365
2004-10-01 to 2005-09-30-91,625USD365
2004-01-23 to 2004-09-30-14,395USD252

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-434,990USD92
2004-01-23 to 2013-12-31-16,999,918USD3631
2012-10-01 to 2012-12-31-131,573USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-10-01 to 2013-12-31188,170USD92
2004-01-23 to 2013-12-3117,103,803USD3631
2012-10-01 to 2012-12-31200,000USD92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-2,327USD92
2004-01-23 to 2013-12-31-7,958USD3631
2012-10-01 to 2012-12-310USD92

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2013-10-01 to 2013-12-3137,484,793shares92
2012-10-01 to 2012-12-3130,240,687shares92

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2013-10-01 to 2013-12-3143,933,759shares92
2012-10-01 to 2012-12-3130,240,687shares92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2013-10-01 to 2013-12-310.01USD/shares92
2012-10-01 to 2012-12-310.01USD/shares92

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-0.01USD/shares92
2012-10-01 to 2012-12-31-0.01USD/shares92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-12-312,135USD
At 2013-09-300USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-10-01 to 2013-12-310USD92
2004-01-23 to 2013-12-315,845,047USD3631
2012-10-01 to 2012-12-310USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-309,608USD92
2004-01-23 to 2013-12-31-30,331,168USD3631
2012-10-01 to 2012-12-31-415,867USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-31148,752USD
At 2013-09-30393,449USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-10-01 to 2013-12-313,287USD92
2004-01-23 to 2013-12-31680,649USD3631
2012-10-01 to 2012-12-3110,225USD92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-311,821,141USD
At 2013-09-301,952,660USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-10-01 to 2013-12-315,180USD92
2004-01-23 to 2013-12-3112,827,976USD3631
2012-10-01 to 2012-12-31127,003USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-3137,640,098shares
At 2013-09-3037,237,588shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-3139,078,440USD
At 2013-09-3038,644,523USD

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-10-01 to 2013-12-31188,170USD92
2004-01-23 to 2013-12-3111,236,288USD3631
2012-10-01 to 2012-12-310USD92

Inspect the source

Entity
ANAVEX LIFE SCIENCES CORP. / CIK 0001314052
Captured
2026-09-20T07:51:32.244Z
SEC response SHA-256
58235b1aa01b2e3fa186f80cce94f8ff6bd171b1d8823aeeecb0ffde54d83b04

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001314052.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))